Viatris Inc.

Organisation

Robert J. Coury Global Center, Canonsburg, PA, United States, 15317

Headquarters

30000

Employees

Health Technology

Industry

Michael Goettler

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Price

Target

Viatris Inc. (VTRS) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Viatris Inc. (VTRS) share price will touch around $15.72 in next 12-months.

Currently 14 wall-street analysts regularly analyze the financials of Viatris Inc. on a frequent basis to provide recommendations along with target share price. 14 analysts offering 12-month price forecasts for Viatris Inc. (VTRS) have a share price target of $15.72. This median of share price forecast represents a 16.89% upside from the latest price of $13.45 as on 06.04.26.

Viatris Inc. (VTRS) Share Price Forecast

Home

US Stocks

Viatris Inc. (VTRS)

Viatris Inc. Stock Forecast

Viatris Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Viatris Inc. (VTRS): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Viatris Inc.'s share price and its median forecast price. As on 06.04.26, the difference is -13.31%

Viatris Inc. Forecast and Target Price

Viatris Inc. (VTRS) Share Price Forecast

Viatris Inc. (VTRS) Price vs Consensus Price Target

Viatris Inc. (VTRS) Share Price Forecast v/s Share Price Today

Viatris Inc. (VTRS): Difference between Current Price & Median Forecasted Price

Viatris Inc. (VTRS) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price